-
South African election results renew debate over identity-based voting
-
Post-election pressures complicate US and Israeli decisions on Iran
-
South African voters report smoother local election but declining IEC trust
-
UN members approve talks on treaty protocol against environmental crime
-
Dolly Parton museum and Nashville hotel open after singer’s death
-
Family-run West Sussex beach café prepares for first winter season
-
George and Amal Clooney attend New York political-comedy reading
-
CT scans reveal health and burial clues from Egypt’s Braided Lady mummy
-
British buyers pay substantial premiums for period-home appearance
-
Oxford faces complaints over lecturer’s classroom attire
-
Thomas Markle released to house arrest after child-abuse-image charge
-
Kyren Wilson and John Higgins reach International Championship snooker final
-
Dawn of War 4 developers chose Adeptus Mechanicus for tactical variety
-
New Zealand and Tonga meet for place in Rugby League World Cup final
-
Italy face unbeaten South Africa in Turin Nations Championship match
-
Reports of unsafe AI-toy responses renew calls for child-safety rules
-
ChatGPT interactive interface feature tested across six custom tools
-
Juneau food network combines difficult supply routes with deep sharing traditions
-
Freshways milk-price cut deepens pressure on UK dairy farms
-
India climbs green-transition ranking after first emissions decline in 25 years
-
Labour and National remain virtually tied as New Zealand vote count advances
-
Trump names Stephen Miller as White House chief of staff after midterm losses
-
The Good Daughter adapts Karin Slaughter thriller with Rose Byrne and Meghann Fahy
-
Restored Albanian tower houses anchor new rural tourism trail
-
Heavy-lift drone evacuates wounded Ukrainian soldier from frontline kill zone
-
Sonia Gandhi reflects on family tragedy and reluctant political career
-
Morrison says West Brom recovered after pressure from successive derby losses
-
Pope Leo begins three-country South American tour in Uruguay
-
Britain considers 2027 state visit for Ukraine’s Zelensky
-
Khawaja says entire Australia camp knew of 2018 ball-tampering plan
-
Anna Miltina Confronted with Racism Allegations on ProSieben Show
-
November Foraging Guide: Edible Mushrooms and Critical Safety Protocols
-
German Auto Giants Face Existential Crisis as China Sales Plummet
-
Microsoft Updates Xbox PC App with 60% Faster Startup and Redesigned Interface
-
Cause of Death Revealed for 'Ellen' Producer Matthew Wright
Verseon Chooses DataKrypto's FHEnom for AI(TM) to Ensure Continuous Encryption of AI-Driven Medical Research and Clinical Trial Data
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
BURLINGAME, CA / ACCESS Newswire / October 1, 2025 / DataKrypto, the creator of the fastest fully homomorphic encryption (FHE) solutions on the market, announced today that Verseon, a drug development innovator, is deploying its cutting-edge FHEnom for AI to ensure the continuous security of AI datasets and proprietary models.
Verseon's team of scientists, biologists, and medical researchers works diligently to create medicines that improve the world's treatment of all major human diseases. AI plays a vital role in Verseon's drug development and clinical trials, and ensuring that highly sensitive data is always protected, throughout AI training and inference, is crucial for maintaining compliance with stringent data privacy regulations.

"DataKrypto's FHEnom for AI gives us a secure, continuously encrypted solution for our AI training, fine-tuning, and real-world usage," said David Kita, CSO of Verseon. "With implementation taking just hours, the solution combines security with convenience and speed, allowing us to focus on our core activities."
"Verseon's mission-critical drug discovery and development work is reliant on its ability to maintain continuous protection of its clinical trial data and proprietary AI models," said Ravi Srivatsav, CEO of DataKrypto. "FHEnom for AI fills the encryption gap by enabling AI training and processing without having to decrypt data, which potentially exposes it to malicious use. We are proud to provide the first solution that gives companies like Verseon confidence and peace of mind with their AI implementations, knowing that their data is always secure."
Building Trust in AI with DataKrypto
FHEnom for AI is an AI-compliant, zero-knowledge framework that safeguards both customized open-source AI models (adapted for specific enterprise needs) and proprietary models, while ensuring the privacy and protection of sensitive data. It defends against malicious activities, misuse, and adversarial manipulation, securing intellectual property and maintaining the confidentiality of critical datasets. DataKrypto's solution helps companies deploying AI overcome concerns about data privacy and model security.
For more information about FHEnom for AI, visit https://datakrypto.com/products/.
About Verseon
Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. Other current methods can find none of these candidates. Verseon's rapidly growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancer. The company's supporters and advisors include multiple Nobel laureates, former heads of R&D at major pharmaceutical companies, and various key opinion leaders in the field of medicine.
About DataKrypto
DataKrypto reimagines AI security for the enterprise. By combining FHEnom™-the fastest, most scalable Fully Homomorphic Encryption technology available-with Trusted Execution Environments (TEEs), DataKrypto enables organizations to adopt, create, and use AI tools with unmatched security and performance. Every model, every dataset-always encrypted. Even the largest AI systems run securely, with performance intact. DataKrypto empowers organizations to embrace AI, ensuring protection at every step. Learn more at www.datakrypto.com.
Media Contact:
Liz Youngs
Trier and Company for DataKrypto
1-843-412-6327
[email protected]
SOURCE: DataKrypto
View the original press release on ACCESS Newswire
L.Harper--AMWN